Assessment guide is useful for all
Mock scenarios and helpful exercises make this book more than an exam guide, says Dr Lizzie Croton. Read more
Manchester-based United Pharmacies has made 80 such applications since launching last November.
Only one, in Widdrington, Northumberland, has so far been accepted by a PCT. But the company has won several others on appeal.
Dr Chris Waite, a partner at the Widdrington Surgery said that, if a pharmacy goes ahead, the practice will lose half its income and the equivalent of half a GP.
A spokeswoman for Northumberland PCT said that there had been ‘no reason to reject the application'. Under current regulations it had no choice but to accept it, she said.
The practice is now challenging the plan before the NHS Litigation Authority (NHSLA).
GPs and pharmacists alike have criticised United's scattergun approach.
Widdrington Surgery acts as a dispensary for 97 per cent of its patients, and fills 6,000 prescriptions a month. Staff say that this accounts for half its income and subsidises other services.
If United's plan goes ahead, the practice will no longer be able to dispense to 80 per cent of its patients. It would be forced to give up dispensing altogether if the recent pharmacy White Paper becomes law.
The NHSLA's decision is expected by mid May.
Comment below and tell us what you think
Mock scenarios and helpful exercises make this book more than an exam guide, says Dr Lizzie Croton. Read more
Requests for pregnancy termination should be handled with sensitivity, writes Dr Mona Kular. Read more
In the first of a regular look at the nMRCGP, Dr Daryl Goodwin explains how to pass the CSA. Read more
Contributed by Dr Jeffery Lee, consultant rheumatologist, Barnet Hospital, Hertfordshire. Read more
Section 1: Epidemiology and classification Chronic kidney disease (CKD) encompasses abnor... Read more
Contributed by Dr Stephan Brincat, specialist registrar, and Dr Rachel Hilton, consultant nephrologi... Read more
Eucreas (vildagliptin + metformin) is a new fixed-dose combination treatment for patients inadequate... Read more
Novartis has launched a new oral hypoglycaemic for the treatment type II diabetes. Read more
Coversyl and Coversyl Plus have been discontinued and replaced by Coversyl Arginine and Coversyl Arg... Read more
Comments
Only registered users may comment. Log in now or register for a free account.